MARKET

KZIA

KZIA

Kazia Therapeuti
NASDAQ
0.3560
-0.0040
-1.11%
Closed 16:00 04/12 EDT
OPEN
0.3397
PREV CLOSE
0.3600
HIGH
0.3779
LOW
0.3374
VOLUME
334.73K
TURNOVER
0
52 WEEK HIGH
1.680
52 WEEK LOW
0.1866
MARKET CAP
9.38M
P/E (TTM)
-0.4808
1D
5D
1M
3M
1Y
5Y
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is the final day of trading this week. PaxMedica stock is rocketing close to 82% after hitting a key milestone in drug development. The biggest pre-market stock movers this morning are earnings reports, stakeholder updates, drug development news and more.
Investorplace · 2d ago
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of NextPlat Corp rose sharply in today’s pre-market trading. The company reported consolidated 2023 revenues of $37.8 million, up 222% year over year. Rent the Runway shares jumped 162% on Thursday after the company reported mixed fourth-quarter financial results.
Benzinga · 2d ago
Weekly Report: what happened at KZIA last week (0401-0405)?
Weekly Report · 6d ago
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Byrna Technologies shares jumped 7.1% to $14.74 on Friday. The company reported better-than-expected first-quarter revenue and announced a CFO transition. MediaCo Holding Inc. Shares jumped 141.7% in today's mid-day session.
Benzinga · 04/05 17:06
Weekly Report: what happened at KZIA last week (0325-0329)?
Weekly Report · 04/01 10:29
Weekly Report: what happened at KZIA last week (0318-0322)?
Weekly Report · 03/25 10:31
Weekly Report: what happened at KZIA last week (0311-0315)?
Weekly Report · 03/18 10:29
Weekly Report: what happened at KZIA last week (0304-0308)?
Weekly Report · 03/11 10:27
More
About KZIA
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.

Webull offers Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ: KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.